Asociación de fabricación aditiva
Asociación de fabricación aditiva

Privacy Policy

This site uses cookies to enhance navigation. By continuing your visit, you accept the use of cookies and our privacy policy.

Accept

NEWS

DATUA, ALONG FAES FARMA, HAS BEEN AWARDED THE FIRST PRIZE IN THE DATATÓN EUSKADI 2024

30 May, 2024
Datua and FAES Farma have been awarded first prize in the Datatón Euskadi 2024, an event that brought together more than 130 people to celebrate the final gala and awards ceremony.

The competition was fierce, with innovative proposals and exceptional presentations. However, the jury chose the solution presented by Datua and FAES Farma for the challenge “Optimization of processes for the development of clinical trials”.

In just three days, the team developed a potentially revolutionary solution for the pharmaceutical industry, significantly speeding up clinical trials and reducing the time needed to develop new drugs. FAES Farma provided in-depth knowledge of the pharmaceutical industry, essential for understanding the challenges and opportunities of the sector. Datua implemented Artificial Intelligence and automation to optimize internal clinical trial preparation processes. The developed system, TrIAls, uses third-party APIs to segment, group and sort relevant information for researchers.

FAES Farma and Datua's solution has the potential to have a significant impact on the pharmaceutical industry, accelerating the development of new drugs and improving people's health. TrIAls allows researchers to save time and effort, focusing on the discovery of new treatments.

This achievement reaffirms Euskadi's position as a leader in the development and application of Artificial Intelligence. Datatón Euskadi has provided a platform for companies and professionals in the Basque Country to collaborate and explore the potential of AI to address real challenges and generate a positive impact on society.

    30/05/2024News

    RELEVANT NEWS

      NEWSLETTER

      Subscribe to our newsletter. Just insert your e-mail and you will receive the latest news.